November 30, 2020
Fremont, Calif.—Verseon is pleased to announce that Dr. Trevor M. Jones CBE has joined the company’s scientific advisory board. Trevor is the joint UK-US Covid Strategy Coordinator and is also a visiting professor at King's College London. He has served on the board of eTherapeutics since 2015 and became its Independent Non-Executive Chairman in 2021. He also serves on the board of life sciences investment company Arix Bioscience plc.
Trevor’s previous experience includes serving as Director of Allegan, Inc., and R&D Director at The Wellcome Foundation Ltd (Wellcome plc). At Wellcome, he was responsible for the development of HIV/AIDS drug AZT as well as Zovirax, Lamictal, Malarone and other medicines.
Among his other advisory and regulatory roles, Trevor has been Director General of the Association of the British Pharmaceutical Industry (“ABPI”), board member of the European Federation of Pharmaceutical Industry Associations (“EFPIA”), and board member of the International Federation of Pharmaceutical Manufacturers Associations (“IFPMA”). He has served on The Medicines Commission, advised the Cabinet Office on the Human Genome Project, and chaired the UK Government Advisory Group on Genetics Research.
About Verseon
To advance global health, Verseon International Corporation (www.verseon.com) has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The company’s drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and advanced AI to develop drug compounds that have never before been synthesized—and are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.